ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Eisai to market anti-Obesity agent in China through CY Biotech
August 01, 2018Eisai will receive a one-time contractual payment and milestone payments dependent upon acquisition of regulatory approval. In addition, Eisai has the option rights to co-promote lorcaserin with CYB in China -
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin recommended to continue
July 27, 2017Cardiovascular outcomes trial of Anti-Obesity Agent Lorcaserin to continue based on recommendation of Independent Data Monitoring Committee after completion of Interim Safety Analysis.
Pharma Sources Insight January 2025
